Liminatus Pharma, Inc. (LIMN) stock
LIMNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMNW
$2.51−0.30 (-10.68%)
Close on Nov 20, 2026Market cap $168.57MP/E –Yield –
Liminatus Pharma gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
No gross profit figures for Liminatus Pharma
Liminatus Pharma has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?